BioSpace News Archive

Partnership includes $35 million up front licensing fees and equity investment, with future milestone payments of up to $388 million plus royalties

Nephros, Inc.(Nasdaq:NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2020 Russell indexes annual reconstitution,

ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc., announced its Klarity-C preservative-free formulation may now be prescribed by Florida’s nearly 2,000 optometrists¹ as a result of the Florida Board of Optometry’s recent additions to its Formulary of Topical Ocular Pharmaceutical Agents.

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two abstracts related to its clinical program for recessive dystrophic epidermolysis bullosa (RDEB) will be presented at the upcoming Society for Pediatric Dermatology (SPD) 45 th Annual Meeting, to be held virtually during July 10-12, 2020. RDEB is a rare connective tissue disorder without an approved treatment, in which p

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its marketing authorization application (MAA) for BRUKINSA®

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will participate in a fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference being held virtually on June 23, 2020. Details of the fireside chat are below: Event:

Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to report important progress towards the commencement of recruitment in the Phase 3 clinical trial of CYP-004, its Cymerus™ mesenchymal stem cell (MSC) product for osteoarthritis

Crown Bioscience today announced their innovative AACR 2020 conference and tradeshow. The virtual event, which runs from June 22-25, will incorporate all of the features of a major scientific conference, with keynote speakers, access to CrownBio’s AACR 2020 posters, as well as a tradeshow booth. To coincide with the AACR Virtual Annual Meeting II, this unique forum will feature the publication of CrownBio’s 13 internal and collaborative AACR 2020

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Guy Goldberg, RedHill’s Chief Business Officer, will present a corporate overview at the Virtual Life Sciences Investor Forum on Thursday, June 25, 2020, at 10 a.m. EDT.

Tempest, an integrated, evidence-based digital recovery program, is launching an expanded membership model to revolutionize the care model for individuals on the spectrum of Alcohol Use Disorder.